Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR(+) NK cell levels correlate with disease outcome

We performed a Phase I clinical trial from October 2007 to October 2009, enrolling patients affected by refractory solid tumors, to determine the maximum tolerated dose (MTD) of interleukin (IL)-2 combined with low dose cyclophosphamide (CTX) and imatinib mesylate (IM). In a companion paper publishe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaput, Nathalie, Flament, Caroline, Locher, Clara, Desbois, Mélanie, Rey, Annie, Rusakiewicz, Sylvie, Poirier-Colame, Vichnou, Pautier, Patricia, Le Cesne, Axel, Soria, Jean-Charles, Paci, Angelo, Rosenzwajg, Michelle, Klatzmann, David, Eggermont, Alexander, Robert, Caroline, Zitvogel, Laurence
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601178/
https://www.ncbi.nlm.nih.gov/pubmed/23525357
http://dx.doi.org/10.4161/onci.23080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3601178/
https://www.ncbi.nlm.nih.gov/pubmed/23525357
http://dx.doi.org/10.4161/onci.23080

Ejemplares similares